Search
for
Sort by
Research 121–150 of 567
- Cutaneous reactions to recombinant cytokine therapy
- Nutrition and Hair
- Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer
- Are the cutaneous manifestations during or due to SARS-CoV-2 infection/COVID-19 frequent or not? Revision of possible pathophysiologic mechanisms
- Diet and hair loss: effects of nutrient deficiency and supplement use
- Clinical and biological impact of the exposome on the skin
- Acquired Zinc Deficiency
- Management of congenital ichthyoses: European guidelines of care, part two
- Graft-versus-host disease
- Dermatologic Manifestations of Human Immunodeficiency Virus Infection
- A Feature-Preserving Hair Removal Algorithm for Dermoscopy Images
- Microneedle-Based Approaches for Skin Disease Treatment
- Skin Conditions in Figure Skaters, Ice-Hockey Players and Speed Skaters
- Gender aspects in skin diseases
- Cutaneous Manifestations of Eating Disorders
- Endocrine-skin interactions
- Involvement of scalp and nails in lupus erythematosus
- Serum Levels of Retinol-Binding Protein 4 and Adiponectin in Women with Polycystic Ovary Syndrome: Associations with Visceral Fat But No Evidence for Fat Mass-Independent Effects on Pathogenesis in This Condition
- Evidence-based approach to cutaneous hyperandrogenism in women
- Novel cosmeceuticals from plants—An industry guided review
- The Clinical Presentation of Systemic Lupus Erythematosus
- A Clinical Approach to Severe Insulin Resistance
- Cutaneous Lesions in Systemic Lupus Erythematosus
- Patients with specific skin disorders who are affected by COVID ‐19: What do experiences say about management strategies? A systematic review
- A Review of hormone-based therapies to treat adult acne vulgaris in women
- Dermatologic manifestations of COVID‐19: a comprehensive systematic review
- Innovative Uses for Zinc in Dermatology
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs
- Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases